Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 03 Dec 2025 | Ulla Schwager Head of Unit | Exchange of views on developments in the pharmaceutical industry and aspects of competition law and policy enforcement in this industry sector | — |
| 03 Dec 2025 | Ulla Schwager Head of Unit | Exchange of views on developments in the pharmaceutical industry and aspects of competition law and policy enforcement in this industry sector | SRC |
| 04 Sept 2025 | Boriša Falatar Cabinet member | HIV prevention | — |
| 04 Sept 2025 | Boriša Falatar Cabinet member | HIV prevention | SRC |
| 01 Jul 2025 | Cecile Billaux Head of Unit | Gilead’s long-acting HIV prevention drug: LENACAPAVIR – access in Africa | — |
| 01 Jul 2025 | Cecile Billaux Head of Unit | Gilead’s long-acting HIV prevention drug: LENACAPAVIR – access in Africa | SRC |
| 20 Jun 2025 | Michael McGrath Commissioner | Exchange of views on issues relating to competitiveness and corporate sustainability | SRC |
| 20 Jun 2025 | Michael McGrath Commissioner | Exchange of views on issues relating to competitiveness and corporate sustainability | — |
| 27 Mar 2025 | Vincenzo Matano Cabinet member | General Exchange on the Company’s Activities | — |
| 27 Mar 2025 | Vincenzo Matano Cabinet member | General Exchange on the Company’s Activities | SRC |
| 19 Jan 2024 | Tove Ernst Cabinet member | Meeting with Spanish Women’s Coalition on Triple Negative Breast Cancer on Europe’s Beating Cancer Plan and EU policies on cancer | — |
| 19 Jan 2024 | Tove Ernst Cabinet member | Meeting with Spanish Women’s Coalition on Triple Negative Breast Cancer on Europe’s Beating Cancer Plan and EU policies on cancer | SRC |
| 22 Mar 2023 | Patricia Reilly Cabinet member | Discussed Gilead’s manufacturing operations in Ireland and globally. Gilead outlined their concerns with the soon to be published EU Pharmaceutical strategy, with particular emphasis on unmet medical needs, regulatory data protection and innovation | SRC |
| 22 Mar 2023 | Patricia Reilly Cabinet member | Discussed Gilead’s manufacturing operations in Ireland and globally. Gilead outlined their concerns with the soon to be published EU Pharmaceutical strategy, with particular emphasis on unmet medical needs, regulatory data protection and innovation | — |
| 11 Jun 2021 | Stella Kyriakides Commissioner | Exchange of views on joint procurement and scientific assessment of Remdesivir | SRC |
| 11 Jun 2021 | Stella Kyriakides Commissioner | Exchange of views on joint procurement and scientific assessment of Remdesivir | — |
| 07 Dec 2020 | Stella Kyriakides Commissioner | Exchange of views, update on Remdesivir | — |
| 07 Dec 2020 | Stella Kyriakides Commissioner | Exchange of views, update on Remdesivir | SRC |
| 16 Oct 2020 | Stella Kyriakides Commissioner | Exchange of views - update on Remdesivir | — |
| 16 Oct 2020 | Stella Kyriakides Commissioner | Exchange of views - update on Remdesivir | SRC |
| 09 Sept 2020 | Stella Kyriakides Commissioner | Discussions/update on Remdesivir | SRC |
| 09 Sept 2020 | Stella Kyriakides Commissioner | Discussions/update on Remdesivir | — |
| 06 Jul 2020 | Stella Kyriakides Commissioner | VC meeting: Exchange of views on the forthcoming Pharmaceutical Strategy | SRC |
| 06 Jul 2020 | Stella Kyriakides Commissioner | VC meeting: Exchange of views on the forthcoming Pharmaceutical Strategy | — |
| 02 Jun 2020 | Stella Kyriakides Commissioner | Update on remdesivir | SRC |
Mission & Goals
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 38 countries worldwide.
EU Legislative Interests
EU initiatives relevant to HIV/AIDS, Hepatitis / Liver diseases, Cell Therapies and oncology - ATMP Regulation - EU IP policy - EU research policy - EU trade policy - Health Systems Performance Assessment - Health Technology Assessment & Market Access - Industrial policy - Outcomes-based healthcare systems - General Pharmaceutical Legislation - EU Biotech Act - Digital Health - Europe's Beating Cancer Plan - SoHO legislation - Sustainable Development Goals - EU4Health - Critical Medicines Act - EU Biotech Act - EU Competitiveness agenda - Sustainability and Green policies
Communication Activities
Organisation of dedicated policy events and policy communications campaigns aimed at raising awareness of HIV, Oncology and Advanced Therapies at EU-level. Participation in similar events and campaigns organised by multi-stakeholder initiatives and partner organisations. Organisation of site visits with EU policymakers to production facilities. Sponsorship of a media campaign and articles carried out and/or published by EU-based policy media.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
European Federation of Pharmaceutical Industries and Associations (EFPIA): http://www.efpia.eu European Confederation of Pharmaceutical Entrepreneurs (EUCOPE): http://www.eucope.org American Chamber of Commerce to the European Union (AMCHAM EU): http://www.amchameu.eu Alliance for Regenerative Medicine (ARM): https://alliancerm.org/
Organisation Members
HIV Outcomes - https://hivoutcomes.eu/ HIV Prevention Alliance - https://hivpreventionalliance.eu/ Transforming Breast Cancer Together - https://tbct.eu/
Additional Information
This estimate includes costs attributable to covered activities, including consulting fees, meeting costs and the pro-rata salary and travel costs of Gilead Sciences' staff involved in representation to the European institutions, based on the proportion of employee time spent on these activities. The two dedicated 100% FTEs started in September 2022 and are calculated pro-rata for the financial year of 2025.